Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
May 03 2018 - 11:00AM
NeuroMetrix, Inc. (Nasdaq:NURO), today reported that preliminary
results from a study of Quell® wearable pain relief in chronic low
back pain will be presented at the 9th World Congress of the World
Institute of Pain in Dublin, Ireland May 9-12, 2018.
The study was conducted by Dr. Robert Jamison and his colleagues
at the Brigham and Women's Hospital Pain Management Center in
Boston, MA. The poster presentation is titled “Efficacy of
high-frequency transcutaneous electrical nerve stimulation for
chronic low back pain: does hypersensitivity matter?” and includes
the following key findings:
- Subjects in the experimental (Quell) group demonstrated reduced
pain intensity compared to control subjects.
- Subjects in the experimental group exhibited reduced pain
interference with function and pain catastrophizing compared to the
control group.
- Subjects in the experimental group with greater sensitivity on
quantitative sensory testing had more disability and higher Quell
use, but sensitivity did not predict pain outcomes.
- Subjects in the experimental group used their device 381 ± 353
hours during the study.
The study was a three-month single site, controlled, randomized
clinical trial. A total of 68 adult patients with a primary
complaint of chronic low back pain were enrolled and randomized
with equal probability to treatment with the Quell device or
"treatment-as usual." Study subjects averaged 46.2 ± 2.7
years of age. All subjects used a smartphone app developed by
the Pain Management Center that helps patients document and manage
their pain. Outcome measures included the Brief Pain
Inventory, the Pain Catastrophizing Scale, the Pain Disability
Index and the Hospital Anxiety and Depression Scale. All
subjects were given Quantitative Sensory Testing at baseline.
According to the Centers for Disease Control and Prevention
(CDC), low back pain is the second most common cause of disability
in US adults. The incidence of low back pain is as high as 12
percent of the general population at any given point in time, and
nearly 25 percent of US adults report having had it at some point
over any one-month period. The condition has a significant economic
impact, with total costs estimated to be up to $200B annually. For
those with chronic low back pain (low back pain persisting for
three or more months), there are few accepted treatments that do
not involve prescription medication, manipulation, invasive
procedures, or surgery.
"Chronic low back pain is a major health problem and represents
a natural application for Quell," said Shai N. Gozani, M.D., Ph.D.,
President and CEO of NeuroMetrix. "The preliminary results from
this study led by Dr. Robert Jamison are encouraging and we look
forward to formal publication of the study findings.”
About Brigham and Women's Hospital Pain Management
Center
Boston's Brigham and Women's Hospital (BWH) is an international
leader in virtually every area of medicine and has been the site of
pioneering breakthroughs that have improved lives around the world.
A major teaching hospital of Harvard Medical School, BWH has a
legacy of excellence that continues to grow year after year. The
Brigham and Women's Hospital Center for Pain Therapy and Research
encompasses two programs: clinical care and education is provided
through the Pain Management Center, and basic science and clinical
research is conducted through the Pain Research Center. The BWH
Pain Management Center is a nationally recognized model for
innovation and excellence.
About Quell
Quell is an advanced, wearable technology for treating chronic
pain. It can be worn during the day while active and at night while
sleeping. Quell is drug-free and has been cleared by the FDA for
treatment of chronic pain without a prescription. Quell users can
personalize and manage therapy discreetly via the Quell app.
Quell also offers health tracking relevant to chronic pain
sufferers including pain, sleep, activity, and gait. Quell users
can synchronize their data with the Quell Health Cloud, which
provides customized feedback and powers one of the world’s largest
chronic pain databases. Quell is available online and through
selectretailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining
neurostimulation and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes.
The company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. The company also markets
DPNCheck®, a rapid point-of-care test for diabetic neuropathy,
which is the most common long-term complication of Type 2 diabetes.
For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024